SD 101 - Dynavax Technologies

Drug Profile

SD 101 - Dynavax Technologies

Alternative Names: SD101 - Dynavax

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine
  • Class Antineoplastics; Oligodeoxyribonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma; Follicular lymphoma; Malignant melanoma
  • Phase I Haematological malignancies
  • No development reported Hepatitis C; Lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma(Recurrent, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 01 Nov 2017 University of California at Davis plans a phase trial for Solid tumours and Lymphoma (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA in January 2018 (NCT03322384)
  • 02 Jun 2017 Updated efficacy, adverse events and pharmacodynamics data from a phase Ib/II trial in Malignant melanoma presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top